Aadi bioscience announces fda approval of its first product fyarro™ for patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (pecoma)

Los angeles, nov. 23, 2021 (globe newswire) -- aadi bioscience, inc. (“aadi”) (nasdaq: aadi), a biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mtor pathway genes, today announced that the u.s. food and drug administration (fda) has approved fyarro™ (sirolimus protein-bound particles for injectable suspension) (albumin-bound) for intravenous use for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (pecoma). fyarro is the first and only fda-approved treatment for advanced malignant pecoma in adults.
AADI Ratings Summary
AADI Quant Ranking